At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed grade IV glioblastoma multiforme
- ✓Diagnosis by surgical biopsy or resection within 5 weeks
- ✓Post-operative contrast-enhanced MRI with MR spectroscopy identifying high-risk area of active tumor
- ✓High-risk tumor area meets SRS criteria: maximum diameter ≤40 mm, >5 mm from optic nerve/chiasm, no brainstem involvement
- ✕Multifocal or recurrent malignant glioma
- ✕Prior in-field radiotherapy to head and neck
- ✕Pregnant or positive pregnancy test
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Conventional Radiotherapy With Stereotactic Radiosurgery to High Risk Tumor Regions as Determined by Functional Imaging in Patients With Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating radiation therapy and stereotactic radiosurgery for Brain and Central Nervous System Tumors. Completed, enrolled 35 participants across 2 sites.
Detailed Summary
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving stereotactic radiosurgery together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving stereotactic radiosurgery together with radiation therapy works in treating patients with glioblastoma multiforme.
Study Details
Timeline
Interventions
No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy